BiotechTube

PBGENE-DMD (IV)

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Conditions

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Trial Timeline

Mar 1, 2026 → Dec 1, 2029

NCT ID
NCT07429240

About PBGENE-DMD (IV)

PBGENE-DMD (IV) is a phase 1/2 stage product being developed by Precision BioSciences for Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07429240. Target conditions include Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07429240Phase 1/2Recruiting

Competing Products

20 competing products in Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from Precision BioSciences

Fludarabine + CyclophosphamidePhase 1/2
33
PBGENE-HBVPhase 1
25
Fludarabine + Cyclophosphamide + NirogacestatPhase 1
25
PBGENE-HBVPre-clinical
15